EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome ...

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property ...

The rumours surrounding Elvis Presley's sudden death have plagued his name for decades, but the sealed autopsy report - which ...

If you are immunocompromised, your immune system is weakened, making you more susceptible to severe illness and infection. Some people are born with a weakened immune system, while others can become ...

Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.

The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency ...

The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency to ...

with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia 1, disorders characterized by very low or absent levels of antibodies and an increased risk of ...

Canada Cashback Programs Business Report 2024-2029: Growing Preference for Immediate Rewards, Economic Pressures, Integration with Digital Payment Solutions Impacts on the $13.65 Billion Industry - ...